Similar articles

• Inhibition of arterial thrombosis and platelet function by nafazatrom.

  Buchanan MR, Blajchman M, Hirsh J. Buchanan MR, et al. Thromb Res. 1982 Oct 15;28(2):157-70. doi: 10.1016/0049-3848(82)90258-4. Thromb Res. 1982. PMID: 6758186
• In vivo and in vitro effects of nafazatrom (Bay g 6575), an antithrombotic compound, on arachidonic acid metabolism in platelets and vascular tissue.

  Fischer S, Struppler M, Weber PC. Fischer S, et al. Biochem Pharmacol. 1983 Jul 15;32(14):2231-6. doi: 10.1016/0006-2952(83)90231-9. Biochem Pharmacol. 1983. PMID: 6688182
• Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.

  Massad L, Plotkine M, Boulu RG. Massad L, et al. Thromb Res. 1988 Jun 1;50(5):617-25. doi: 10.1016/0049-3848(88)90320-9. Thromb Res. 1988. PMID: 3137682
• [Systemic effects of thrombolytic therapy].

  Balduini CL, Gamba G, Bertolino G, Noris P, Previtali M, Ascari E. Balduini CL, et al. Haematologica. 1991 Jun;76 Suppl 3:281-90. Haematologica. 1991. PMID: 1752524 Review. Italian. No abstract available.
• [Pharmacologic principles of fibrinolytic therapy].

  Markwardt F. Markwardt F. Z Gesamte Inn Med. 1987 Sep 1;42(17):473-8. Z Gesamte Inn Med. 1987. PMID: 3318182 Review. German.